CEMEDIUM SIGNALFINANCIAL10-K

CE shows mixed financial performance with dramatically improved cash position (+181%) but continued substantial losses and declining profitability metrics.

The massive cash increase suggests either successful financing activities or asset sales, providing near-term liquidity cushion during a challenging operational period. However, the company remains deeply unprofitable with worsening operating losses despite cost reduction efforts, indicating ongoing fundamental business challenges that require monitoring.

Comparing 2026-02-24 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

CE's financial picture presents a stark contrast between improved liquidity and deteriorating operations. While cash surged 181% to $1.5B and operating cash flow grew 18.6%, the company posted substantial losses with net income at -$1.2B and operating income at -$786M, accompanied by declining gross profit (-17.1%) and reduced stockholders' equity (-21.8%). The combination of strong cash generation, reduced capital expenditures, and persistent large losses suggests a company in transition, potentially divesting assets or restructuring operations while struggling with core profitability.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+181.3%
$536.0M$1.5B

Cash position surged 181.3% — strong cash generation or capital raise providing significant financial cushion.

Net Income
P&L
+23.5%
-$1.5B-$1.2B

Net income grew 23.5% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
-21.8%
$5.2B$4.0B

Equity decreased 21.8% — buybacks or losses reducing book value, monitor solvency ratios.

Capital Expenditure
Cash Flow
-21.1%
$435.0M$343.0M

Capex reduced 21.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+18.6%
$966.0M$1.1B

Operating cash flow grew 18.6% — strong conversion of earnings to cash, healthy business fundamentals.

Accounts Receivable
Balance Sheet
-17.8%
$1.1B$922.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Gross Profit
P&L
-17.1%
$2.4B$2.0B

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Operating Income
P&L
-12.8%
-$697.0M-$786.0M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

SG&A Expense
P&L
-12.7%
$1.0B$899.0M

SG&A reduced 12.7% — improved cost efficiency or headcount reduction improving operating margins.

Current Assets
Balance Sheet
+10.7%
$5.1B$5.7B

Current assets grew 10.7% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-21
ADDED
The number of outstanding shares of the registrant's common stock, $0.0001 par value, as of February 20, 2026 was 109,571,972 .
Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 7A.
As of December 31, 2025, we employed 11,434 people worldwide.
These global trends drive a range of needed customer solutions, such as vehicle lightweighting, precise components, aesthetics and appearance, low emissions, heat resistance and low-friction for medical applications, that we are uniquely positioned to address with our materials portfolio.
Our nylon products include Celanyl (PA6, PA6.6), FRIANYL (flame retardant PA6, PA66, PPA compounds), ECOMID (recycled polyamide), Zytel (PA, PA6, PA66, PA610, PA612), Zytel high temperature nylons, (PPA) and Zytel long-chain polyamides and are used in automotive, appliances, electrical, medical, industrial and consumer applications due to their mechanical properties, dimensional stability, high impact resistance, resistance to organic solvents, high wear and fatigue resistance even at high temperatures, and easy processing and molding.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant's common stock, $0.0001 par value, as of February 17, 2025 was 109,332,326 .
Management's Discussion and Analysis of Financial Condition and Results of Operations 36 Item 7A.
As of December 31, 2024, we employed 12,163 people worldwide.
Ascend Performance Materials LLC BASF SE Daicel Corporation ("Daicel") DOMO Chemicals Kingfa Science and Technology Korea Petrochemical Ind.
Co, Ltd ("KPIC") Envalior GmbH SABIC Innovative Plastics Solvay S.A.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →